menu
    • menu

    Company profile for Avobis Bio

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Avobis Bio is dedicated to transforming patients' lives by developing implantable biological therapies that promote tissue healing. We are pioneering the first implantable cell therapy specifically designed to heal perianal fistulas, a condition that significantly impacts quality of life. Established as a joint venture between Mayo Clinic and W. L. Gore & Associates, Inc., Avobis Bio combines clinical expertise with advanced m...
    Avobis Bio is dedicated to transforming patients' lives by developing implantable biological therapies that promote tissue healing. We are pioneering the first implantable cell therapy specifically designed to heal perianal fistulas, a condition that significantly impacts quality of life. Established as a joint venture between Mayo Clinic and W. L. Gore & Associates, Inc., Avobis Bio combines clinical expertise with advanced material science to create innovative, curative therapies for patients with challenging, non-healing wounds.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Avobis BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    551 Paper Mill Rd. Newark, DE 19711
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avobisbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Avobis Bio To Present Expanded STOMP2 Trial Results At ECCO
    Avobis Bio To Present Expanded STOMP2 Trial Results At ECCO

    29 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avobis-bio-announces-expanded-primary-analysis-results-from-the-randomized-multicenter-stomp2-clinical-trial-to-be-presented-at-european-crohns-and-colitis-organisation-ecco-congress-302673821.html

    PR NEWSWIRE
    29 Jan 2026
    Share Share
    Avobis Bio Unveils Positive STOMP2 Trial Results At ACG Meeting
    Avobis Bio Unveils Positive STOMP2 Trial Results At ACG Meeting

    29 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avobis-bio-presents-positive-primary-analysis-results-from-the-randomized-multicenter-stomp2-clinical-trial-at-a-plenary-session-of-the-american-college-of-gastroenterologys-annual-scientific-meeting-302598288.html

    PR NEWSWIRE
    29 Oct 2025
    Share Share
    FDA Designates Avobis Bio's AVB-114 For Crohn's Fistulas
    FDA Designates Avobis Bio's AVB-114 For Crohn's Fistulas

    03 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-rmat-designation-to-avobis-bios-implantable-cell-therapy-avb-114-for-crohns-perianal-fistulas-302574412.html

    PR NEWSWIRE
    03 Oct 2025
    Share Share
    Avobis Completes Primary Analysis of AVB-114 in Crohn's Fistulas
    Avobis Completes Primary Analysis of AVB-114 in Crohn's Fistulas

    08 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avobis-bio-completes-primary-analysis-of-stomp-ii-randomized-clinical-trial-of-avb-114-in-crohns-perianal-fistulas-302522407.html

    PR NEWSWIRE
    08 Aug 2025
    Share Share
    Avobis Bio Gets FDA Fast Track for AVB-114 Cell Therapy
    Avobis Bio Gets FDA Fast Track for AVB-114 Cell Therapy

    27 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avobis-bio-receives-fda-fast-track-designation-for-avb-114-implantable-cell-therapy-for-crohns-perianal-fistulas-302386006.html

    PR NEWSWIRE
    27 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search